ArticleScientific reports2025
Recovery of glioblastoma cells derived from patients after a decade of cryopreservation for drug response studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recovery and Expansion of Patient-Derived Glioblastoma Cells After Long-term Cryopreservation.Bio-protocol · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patient-derived glioblastoma cells (GBMs) are essential for drug screening and personalized medicine. Limited patient sample availability requires the use of long-term cryopreserved GBM cells. However, current methods for recovering GBM cells after an extended period of cryopreservation are generally inefficient, resulting in poor survival of these cells. Therefore, this study sought to optimize a culture procedure to improve the recovery and growth of patient-derived GBM cells after long-term cryostorage. We show that the use of Matrigel with an increased percentage of fetal bovine serum significantly improves the viability and subsequent expansion of GBM cells, which were cryopreserved for more than 10 years, compared to standard culture methods. The enhanced growth is associated with an increase in the expression of YAP and TLR4, the key regulators of cell proliferation, in these GBM cells. These recovered GBM cells were successfully used for chemotherapeutic drug testing, specifically temozolomide (TMZ), in 2D and 3D spheroid culture systems. We believe that our optimized protocol offers a valuable tool to increase the availability of patient-derived GBM cells by allowing efficient recovery of long-term cryopreserved GBM cells for research and personalized drug testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.